The pathogenesis of dengue

Current Opinion in Infectious Diseases

Volumn 26, Issue 3, 2013, Pages 284-289

  Yacoub, Sophie ^a,b   Mongkolsapaya, Juthathip ^a,c   Screaton, Gavin ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

dengue; genetics; immunity; pathogenesis; review

Indexed keywords

CYTOKINE; VIRULENCE FACTOR;

DENGUE; DENGUE VIRUS; GENETIC PREDISPOSITION; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; INCIDENCE; INFECTION RISK; INFECTION SENSITIVITY; PATHOGENESIS; REVIEW; T LYMPHOCYTE;

EID: 84876818202     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835fb938     Document Type: Review

References (58)

1. WHO. Dengue: guidelines for treatment, prevention and control. Geneva: World Health Organization; 2009.
2. Simmons CP, Farrar JJ, Nguyen v V, Wills B. Dengue. N Engl J Med 2012; 366:1423-1432.
3. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977; 265:739-741.
4. Halstead SB. Controversies in dengue pathogenesis. Paediatr Int Child Health 2012; 32 (Suppl 1):5-9.
5. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476-481.
6. Chau TN, Quyen NT, Thuy TT, et al. Dengue in Vietnamese infants: results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 2008; 198:516-524.
7. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9.
8. Kuhn RJ, Zhang W, Rossmann MG, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002; 108:717- 725.
9. Shrestha B, Brien JD, Sukupolvi-Petty S, et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 2010; 6:e1000823.
10. Wahala WM, Donaldson EF, de Alwis R, et al. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog 2010; 6:e1000821.
11. Guzman MG, Hermida L, Bernardo L, et al. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 2010; 9:137-147.
12. Williams KL, Wahala WM, Orozco S, et al. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 2012; 429:12-20.
13. Midgley CM, Bajwa-Joseph M, Vasanawathana S, et al. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol 2011; 85:410-421.
14. Wahala WM, Huang C, Butrapet S, et al. Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J Virol 2012; 86:4019-4023.
15. de Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 2012; 109:7439-7444.
16. Dowd KA, Jost CA, Durbin AP, et al. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog 2011; 7:e1002111.
17. Austin SK, Dowd KA, Shrestha B, et al. Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog 2012; 8:e1002930.
18. Midgley CM, Flanagan A, Tran HB, et al. Structural analysis of a dengue crossreactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J Immunol 2012; 188:4971-4979.
19. Lok SM, Kostyuchenko V, Nybakken GE, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 2008; 15:312-317.
20. Beltramello M, Williams KL, Simmons CP, et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010; 8:271- 283.
21. Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328:745- 748.
22. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, et al. Immature dengue virus: a veiled pathogen? PLoS Pathog 2010; 6:e1000718.
23. Mongkolsapaya J, Dejnirattisai W, Xu XN, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003; 9:921-927.
24. Screaton G, Mongkolsapaya J. T cell responses and dengue haemorrhagic fever. Novartis Found Symp 2006; 277:164-171; discussion 171-166, 251-253.
25. Duangchinda T, Dejnirattisai W, Vasanawathana S, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A 2010; 107:16922-16927.
26. Butthep P, Chunhakan S, Yoksan S, et al. Alteration of cytokines and chemokines during febrile episodes associated with endothelial cell damage and plasma leakage in dengue hemorrhagic fever. Pediatr Infect Dis J 2012; 31:e232-e238.
27. Appanna R, Wang SM, Ponnampalavanar SA, et al. Cytokine factors present in dengue patient sera induces alterations of junctional proteins in human endothelial cells. Am J Trop Med Hyg 2012; 87:936-942.
28. Patkar C, Giaya K, Libraty DH. Dengue virus type 2 modulates endothelial barrier function through CD73. Am J Trop Med Hyg 2013; 88:89-94.
29. Friberg H, Burns L, Woda M, et al. Memory CD8 T cells from naturally acquired primary dengue virus infection are highly cross-reactive. Immunol Cell Biol 2011; 89:122-129.
30. Testa JS, Shetty V, Sinnathamby G, et al. Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response. J Infect Dis 2012; 205:647- 655.
31. Lindow JC, Borochoff-Porte N, Durbin AP, et al. Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans. PLoS Negl Trop Dis 2012; 6:e1742.
32. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559- 1567.
33. Fried JR, Gibbons RV, Kalayanarooj S, et al. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis 2010; 4:e617.
34. Rico-Hesse R. Dengue virus virulence and transmission determinants. Curr Top Microbiol Immunol 2010; 338:45-55.
35. Rico-Hesse R, Harrison LM, Salas RA, et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 1997; 230:244-251.
36. Anez G, Morales-Betoulle ME, Rios M. Circulation of different lineages of dengue virus type 2 in Central America, their evolutionary time-scale and selection pressure analysis. PLoS One 2011; 6:e27459.
37. Leitmeyer KC, Vaughn DW, Watts DM, et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 1999; 73:4738-4747.
38. de Borba L, Strottmann DM, de Noronha L, et al. Synergistic interactions between the NS3(hel) and E proteins contribute to the virulence of dengue virus type 1. PLoS Negl Trop Dis 2012; 6:e1624.
39. Zhang A, Chinnawirotpisan P, Tang Y, et al. Intra-genotypic variation of predominant genotype II strains of dengue type-3 virus isolated during different epidemics in Thailand from 1973 to 2001. Virus Genes 2012. [Epub ahead of print]
40. Adams B, Holmes EC, Zhang C, et al. Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci U S A 2006; 103:14234-14239.
41. OhAinle M, Balmaseda A, Macalalad AR, et al. Dynamics of dengue disease severity determined by the interplay between viral genetics and serotypespecific immunity. Sci Transl Med 2011; 3:114ra128.
42. Sakuntabhai A, Turbpaiboon C, Casademont I, et al. A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet 2005; 37:507-513.
43. Vejbaesya S, Luangtrakool P, Luangtrakool K, et al. TNF and LTA gene, allele, and extended HLA haplotype associations with severe dengue virus infection in ethnic Thais. J Infect Dis 2009; 199:1442-1448.
44. Stephens HA. HLA and other gene associations with dengue disease severity. Curr Top Microbiol Immunol 338:99-114.
45. Loke H, Bethell D, Phuong CX, et al. Susceptibility to dengue hemorrhagic fever in Vietnam: evidence of an association with variation in the vitamin D receptor and Fc gamma receptor IIa genes. Am J Trop Med Hyg 2002; 67:102-106.
46. Wang L, Chen RF, Liu JW, et al. DC-SIGN (CD209) Promoter-336 A/G polymorphism is associated with dengue hemorrhagic fever and correlated to DC-SIGN expression and immune augmentation. PLoS Negl Trop Dis 2011; 5:e934.
47. Simmons CP, Popper S, Dolocek C, et al. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis 2007; 195:1097-1107.
48. Stephens HA, Klaythong R, Sirikong M, et al. HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 2002; 60:309-318.
49. Appanna R, Ponnampalavanar S, Lum Chai See L, Sekaran SD. Susceptible and protective HLA class 1 alleles against dengue fever and dengue hemorrhagic fever patients in a Malaysian population. PLoS One 2010; 5:e13029.
50. Loke H, Bethell DB, Phuong CX, et al. Strong HLA class I: restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J Infect Dis 2001; 184:1369-1373.
51. Monteiro SP, do Brasil PE, CabelloGM, et al. HLA-A-01 allele: a risk factor for dengue haemorrhagic fever in Brazil's population. Mem Inst Oswaldo Cruz 2012; 107:224-230.
52. Lund O, Nascimento EJ, Maciel M Jr, et al. Human leukocyte antigen (HLA) class I restricted epitope discovery in yellow fewer and dengue viruses: importance of HLA binding strength. PLoS One 2011; 6:e26494.
53. Duan ZL, Li Q, Wang ZB, et al. HLA-A-0201-restricted CD8 T-cell epitopes identified in dengue viruses. Virol J 2012; 9:259.
54. Khor CC, Chau TN, Pang J, et al. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nat Genet 2011; 43:1139-1141.
55. Anders KL, Nguyet NM, Chau NV, et al. Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 2011; 84:127-134.
56. Pang J, Salim A, Lee VJ, et al. Diabetes with hypertension as risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic: a case control study. PLoS Negl Trop Dis 2012; 6:e1641.
57. Figueiredo MA, Rodrigues LC, Barreto ML, et al. Allergies and diabetes as risk factors for dengue hemorrhagic fever: results of a case control study. PLoS Negl Trop Dis 2010; 4:e699.
58. Thai KT, Nishiura H, Hoang PL, et al. Age-specificity of clinical dengue during primary and secondary infections. PLoS Negl Trop Dis 2011; 5:e1180.